CONROE,
Texas, July 30, 2024 /PRNewswire/ -- VGXI, Inc.,
a leading contract developer and manufacturer (CDMO) specializing
in nucleic acid biopharmaceuticals, including gene therapies, DNA
vaccines, and RNA medicines, is proud to announce its selection as
a member of Rapid Response Partnership Vehicle (RRPV) which
supports the Biomedical Advanced Research and Development Authority
(BARDA) in its objective to accelerate Medical Countermeasure (MCM)
product and technology development to address evolving needs
including pandemic influenza, emerging infectious diseases, and
other biological threats. With more than two decades of experience
in plasmid DNA manufacturing, VGXI has the largest plasmid
manufacturing capacity (4000L) in the world from its two
state-of-the-art facilities covering 160,000 sq. Ft.
Young Park, the CEO of VGXI,
stated, "We are honored to be accepted as a member of RRPV. We have
a track record to be in the forefront of global response for
manufacturing vaccines needed for infectious disease like
Influenza, Ebola, MERS and COVID19. This gives us an opportunity to
happily support the RRPV members and any partners in the US
Government to protect our country from any future pandemics. VGXI
is open for partnerships to support nucleic acid-based
manufacturing and provide end-to-end solutions under one roof."
ABOUT VGXI
With over 20 years of experience VGXI, Inc. is a leading provider
of plasmid DNA manufacturing and development services. The company
has a reputation of success in manufacturing DNA products under
cGMP conditions for clinical trials in the US, EU, Asia, Canada,
and Australia, and its cGMP and
non-GMP products have passed rigorous reviews by several
international regulatory agencies. VGXI's ability to work with
unique requirements and create custom manufacturing solutions is
based on its patented manufacturing process, flexible cGMP
production facility, and highly experienced development team. VGXI,
Inc. is a GeneOne company. To learn more,
visit https://www.vgxii.com.
ABOUT GENEONE LIFE SCIENCE
GeneOne Life Science Inc. ("GeneOne" KOSPI: 011000) headquartered
in Seoul, South Korea is an
international biotechnology company and a leading contract
manufacturer of DNA plasmids for use in vaccines, gene therapies,
and cell therapies. GeneOne has recently expanded into the
manufacture and development of mRNA. GeneOne has maintained a focus
on vaccines against emerging infectious diseases to address global
needs, including in resource challenged regions. Its small molecule
portfolio of immunomodulators address diseases such as prevention
of upper respiratory bacterial and viral diseases, and treatment of
autoimmune and inflammatory diseases. GeneOne has three products
against COVID-19 in clinical development: GLS-5310 DNA vaccine
(Phase I/IIa), GLS-1200 nasal spray to prevent COVID-19 infection
(Phase II), and GLS-1027 to prevent the inflammation and clinical
worsening for those infected with COVID-19 (Phase II). For more
information, visit https://www.genels.com.
CONTACT: Justin Smith, Director
of Marketing, jcsmith@vgxii.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/vgxi-accepted-as-a-member-of-the-us-governments-rapid-response-partnership-vehicle-rrpv-302209016.html
SOURCE VGXI, Inc.